This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, R. N.
Right arrow Articles by Ross, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, R. N.
Right arrow Articles by Ross, J. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2006, p. 2583-2586, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.01432-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Activity of Retapamulin (SB-275833), a Novel Pleuromutilin, against Selected Resistant Gram-Positive Cocci

Ronald N. Jones,1,2 Thomas R. Fritsche,1 Helio S. Sader,1 and James E. Ross1*

JMI Laboratories, North Liberty, Iowa 52317,1 Tufts University School of Medicine, Boston, Massachusetts 021112

Received 7 November 2005/ Returned for modification 25 January 2006/ Accepted 12 April 2006

Retapamulin (SB-275833), the first pleuromutilin to be developed for human topical use, was tested against a selected population of staphylococci and ß-hemolytic streptococci. The MIC90 results for retapamulin were 0.12 µg/ml for Staphylococcus aureus and ≤0.03 µg/ml for Streptococcus pyogenes; no cross-resistance was observed for organism subsets resistant to oxacillin, erythromycin, or mupirocin.

* Corresponding author. Mailing address: JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317. Phone: (319) 665-3370. Fax: (319) 665-3371. E-mail: jim-ross{at}jmilabs.com.

Antimicrobial Agents and Chemotherapy, July 2006, p. 2583-2586, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.01432-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Traczewski, M. M., Brown, S. D. (2008). Proposed MIC and Disk Diffusion Microbiological Cutoffs and Spectrum of Activity of Retapamulin, a Novel Topical Antimicrobial Agent. Antimicrob. Agents Chemother. 52: 3863-3867 [Abstract] [Full Text]  
  • (2008). {blacktriangledown}Retapamulin for impetigo and other infections. DTB 46: 76-79 [Abstract] [Full Text]  
  • Miller, K., Dunsmore, C. J., Fishwick, C. W. G., Chopra, I. (2008). Linezolid and Tiamulin Cross-Resistance in Staphylococcus aureus Mediated by Point Mutations in the Peptidyl Transferase Center. Antimicrob. Agents Chemother. 52: 1737-1742 [Abstract] [Full Text]  
  • Champney, W. S., Rodgers, W. K. (2007). Retapamulin Inhibition of Translation and 50S Ribosomal Subunit Formation in Staphylococcus aureus Cells. Antimicrob. Agents Chemother. 51: 3385-3387 [Abstract] [Full Text]  
  • Davidovich, C., Bashan, A., Auerbach-Nevo, T., Yaggie, R. D., Gontarek, R. R., Yonath, A. (2007). Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity. Proc. Natl. Acad. Sci. USA 104: 4291-4296 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»